Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 1, 2002, Pages 101-110

  Walker, Ellen A ^a,b   Young, Alice M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CLOCINNAMOX; FENTANYL; MORPHINE; MU OPIATE RECEPTOR; NALBUPHINE; OPIATE AGONIST; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATION LEARNING; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ALGORITHMS; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; CINNAMATES; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FENTANYL; MALE; MORPHINE; MORPHINE DERIVATIVES; NALBUPHINE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU;

EID: 0036088563     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.302.1.101     Document Type: Article

References (43)

1. Assessment of relative intrinsic activity of μ-opioid analgesics in vivo by using β-funaltrexamine
2. Noncompetitive nature of the antagonistic mechanism responsible for tolerance development to opiate-induced analgesia
3. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and μ-receptor binding in mice
4. The effect of the irreversible μ-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA
5. Magnitude of tolerance to fentanyl is independent of μ-opioid receptor density
6. Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea
7. Opioid receptor reserve in normal and morphine tolerant guinea pig ileum myenteric plexus
8. Clocinnamox: A novel, systemically active, irreversible opioid antagonist
9. The effect of intrinsic efficacy on opioid tolerance
10. The development of tolerance to morphine in the rat
11. Beta-funaltrexamine antagonizes the discriminative stimulus effects of morphine but not naltrexone in pigeons
12. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes
13. Effects of beta-funaltrexamine in normal and morphine-dependent rhesus monkeys: Observational studies
14. Stimulus properties of opioids with mixed agonist and antagonist activity
15. Antagonism of morphine-like discriminative effects by β-funaltrexamine
16. The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter
17. Receptor density and recycling affect the rate of agonist induced desensitization of μ-opioid receptor
18. Meperidine effects on schedule-controlled responding
19. The mu opioid irreversible antagonist β-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ-opioid receptor
20. Development of tolerance to the analgesic activity of μ-agonists after continuous infusion of morphine, meperidine, or fentanyl in rats
21. 3H]DAMGO binding in rats
22. Discriminative stimulus effects of the mixed-opioid agonist/ antagonist dezocine: Cross-substitution by μ- and δ-opioid agonists
23. Discriminative stimulus effects of butorphanol: Influence of training dose on the substitution patterns produced by μ-, κ-, and δ-opioid agonists
24. Opioids and rate of positively reinforced behavior: Differential antagonism by naltrexone
25. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment
26. A modification of receptor theory
27. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids
28. Cross-tolerance to etorphine differentiates μ-opioid agonists in a rat tail withdrawal assay
29. 2 analysis in rats treated with either clocinnamox or morphine
30. Tolerance and cross-tolerance to morphine-like stimulus effects of μ-opioids in rats
31. Discriminative-stimulus effects of the low efficacy μ-agonist nalbuphine
32. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats
33. Buprenorphine antagonism of μ-opioids in the rhesus monkey tail-withdrawal procedure
34. In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay
35. Tolerance to morphine-like stimulus effects of μ-opioid agonists
36. Discriminative stimulus effects of morphine: Effects of training dose on agonist and antagonist effects of μ-opioids
37. Tolerance to morphine stimulus control: Role of morphine maintenance dose
38. Mechanism of clocinnamox blockade of opioid receptors: Evidence from in vitro and ex vivo binding and behavioral assays
39. In vivo determination of μ-opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox
40. Receptor reserve and affinity of μ-opioid agonists in mouse antinociception: Correlation with receptor binding
41. Use of β-funaltrexamine to determine μ-opioid receptor involvement in the analgesic activity of various opioid ligands